http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 09:28:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Press+Releases/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html <p><strong>These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead</strong></p><p>DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=wl3_PN3myku2BqC9ZA8KdwRQhoFy7JX2tjD_rzIGXLTf3Ww4Tfm08pTTYbNZLGVqQjgjRcc8N9zs7nkBreism6TMsRuN4b752RYky1D-skI=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – <a href="https://www.globenewswire.com/Tracker?data=YQdqyOQz5bR1zhmb8hbrWLc3eZgUgwXN4zZ2eCuixRxIaF2Qbx7v4ro93ypc4wqHafcOW1S_rH4e6SAxFy6P3SSlifBcXL2y_Y5D4lOYsCk=" rel="nofollow" target="_blank"><strong>Eli Lilly</strong></a><strong> (NYSE:LLY)</strong> has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.</p> <p>The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary http://www.streetinsider.com/Globe+Newswire/Lilly%E2%80%99s+Cancer+Bombshell+Sparks+Hunt+for+the+Next+Oncology+Stock+Set+to+Explode/26580422.html Mon, 01 Jun 2026 09:05:00 -0400 LLY LLY NTHI NTHI OLMA OLMA PFE http://www.streetinsider.com/Press+Releases/The+Next+Great+AI+Revolution+May+Be+Drug+Delivery/26571385.html <p>DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Rhw0fAJBWplltGSrRRBIhgrnGkwlkuO7En-mZ7I0LyCBhAUvy6zxfKZMJBFqACoIWK6bVGhtA17OB70ES2AZGQS_TVEBGadA1XtMSUk1yN4=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics.</p> <p>The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous http://www.streetinsider.com/Press+Releases/The+Next+Great+AI+Revolution+May+Be+Drug+Delivery/26571385.html Fri, 29 May 2026 09:05:00 -0400 NTHI http://www.streetinsider.com/Globe+Newswire/The+Next+Great+AI+Revolution+May+Be+Drug+Delivery/26571385.html <p>DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Rhw0fAJBWplltGSrRRBIhgrnGkwlkuO7En-mZ7I0LyCBhAUvy6zxfKZMJBFqACoIWK6bVGhtA17OB70ES2AZGQS_TVEBGadA1XtMSUk1yN4=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics.</p> <p>The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous http://www.streetinsider.com/Globe+Newswire/The+Next+Great+AI+Revolution+May+Be+Drug+Delivery/26571385.html Fri, 29 May 2026 09:05:00 -0400 NTHI http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html <p>DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=_iDW8Dch89U4ejPn0CxB3M1W22CmVrisY403utimkY-OD4tPa53tzYuQJIEI2zOHODPW8AHv4qSNyOhV8D3zg4g8Y_6WVoGyHqZ_Kg2oPFE=" rel="nofollow" target="_blank">www.247marketnews.com</a>) – NeOnc Technologies (NASDAQ:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=WLLktMBjhuPuw12qMMgImtRSQR_gWq1F9nLVpp_Sq5JTjKW_cZ00o7aaQvwlRRL2WAOSWf47sjRBaHOQJweOw1fVMn-SEsBQh1fbhFJ5d_U=" rel="nofollow" target="_blank">NTHI</a>), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=kxvngDSndCv9nd9shjXss7l9vaNJ3QoVXHdZpCPfnXe6dXHcOeUI-qqFoaX0T3ppaaUoIXQmkvj6SZCMI7fCofBiHMbVHV4PkWxJb5B9UNu8a1iuqUzztT5JQis6J8mvRA3owL71OpctzWL56pgJngLFgh8_PM15_RKKNFZcJ98=" rel="nofollow" target="_blank">Maxim Group</a> and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company’s current market position. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8CYS9gaNbFhCF1-Aasg7-jEM2Kg9EucQzpPRYC2HlpvHhpk5kRDnzjpgO9Cg2zTwYJaR-3s30sfrOWHGEIYeLKt48Az0zT_INApSeTqnzL3gSazBT1ShHpNH5D2f-0tv0ynp-aHUqWfI5kM3QpjwId1emLkS5DsyO5zS1WJvM48=" rel="nofollow" http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html Tue, 19 May 2026 10:28:00 -0400 A.50208788 NTHI O.09748147 O.71329185 http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html <p>DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=_iDW8Dch89U4ejPn0CxB3M1W22CmVrisY403utimkY-OD4tPa53tzYuQJIEI2zOHODPW8AHv4qSNyOhV8D3zg4g8Y_6WVoGyHqZ_Kg2oPFE=" rel="nofollow" target="_blank">www.247marketnews.com</a>) – NeOnc Technologies (NASDAQ:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=WLLktMBjhuPuw12qMMgImtRSQR_gWq1F9nLVpp_Sq5JTjKW_cZ00o7aaQvwlRRL2WAOSWf47sjRBaHOQJweOw1fVMn-SEsBQh1fbhFJ5d_U=" rel="nofollow" target="_blank">NTHI</a>), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=kxvngDSndCv9nd9shjXss7l9vaNJ3QoVXHdZpCPfnXe6dXHcOeUI-qqFoaX0T3ppaaUoIXQmkvj6SZCMI7fCofBiHMbVHV4PkWxJb5B9UNu8a1iuqUzztT5JQis6J8mvRA3owL71OpctzWL56pgJngLFgh8_PM15_RKKNFZcJ98=" rel="nofollow" target="_blank">Maxim Group</a> and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company’s current market position. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8CYS9gaNbFhCF1-Aasg7-jEM2Kg9EucQzpPRYC2HlpvHhpk5kRDnzjpgO9Cg2zTwYJaR-3s30sfrOWHGEIYeLKt48Az0zT_INApSeTqnzL3gSazBT1ShHpNH5D2f-0tv0ynp-aHUqWfI5kM3QpjwId1emLkS5DsyO5zS1WJvM48=" rel="nofollow" http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html Tue, 19 May 2026 10:28:00 -0400 A.50208788 NTHI O.09748147 O.71329185 http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html <p>DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=_iDW8Dch89U4ejPn0CxB3M1W22CmVrisY403utimkY-OD4tPa53tzYuQJIEI2zOHODPW8AHv4qSNyOhV8D3zg4g8Y_6WVoGyHqZ_Kg2oPFE=" rel="nofollow" target="_blank">www.247marketnews.com</a>) – NeOnc Technologies (NASDAQ:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=WLLktMBjhuPuw12qMMgImtRSQR_gWq1F9nLVpp_Sq5JTjKW_cZ00o7aaQvwlRRL2WAOSWf47sjRBaHOQJweOw1fVMn-SEsBQh1fbhFJ5d_U=" rel="nofollow" target="_blank">NTHI</a>), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.</p> <p><a target="_blank" href="https://www.globenewswire.com/Tracker?data=kxvngDSndCv9nd9shjXss7l9vaNJ3QoVXHdZpCPfnXe6dXHcOeUI-qqFoaX0T3ppaaUoIXQmkvj6SZCMI7fCofBiHMbVHV4PkWxJb5B9UNu8a1iuqUzztT5JQis6J8mvRA3owL71OpctzWL56pgJngLFgh8_PM15_RKKNFZcJ98=" rel="nofollow" target="_blank">Maxim Group</a> and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company’s current market position. <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8CYS9gaNbFhCF1-Aasg7-jEM2Kg9EucQzpPRYC2HlpvHhpk5kRDnzjpgO9Cg2zTwYJaR-3s30sfrOWHGEIYeLKt48Az0zT_INApSeTqnzL3gSazBT1ShHpNH5D2f-0tv0ynp-aHUqWfI5kM3QpjwId1emLkS5DsyO5zS1WJvM48=" rel="nofollow" http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Gains+Growing+Institutional+Support+Ahead+of+Key+Brain+Cancer+Clinical+Milestones/26519182.html Tue, 19 May 2026 10:28:00 -0400 A.50208788 NTHI O.09748147 O.71329185